Histone Methyltransferase EZH2: A Potential Therapeutic Target for Kidney Diseases
Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme that catalyzes the addition of methyl groups to histone H3 at lysine 27, leading to gene silencing. Mutation or over-expression of EZH2 has been linked to many cancers including renal carcinoma. Recent studies have sho...
Main Authors: | Tingting Li, Chao Yu, Shougang Zhuang |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-02-01
|
Series: | Frontiers in Physiology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphys.2021.640700/full |
Similar Items
-
Histone Methyltransferases as Therapeutic Targets for Kidney Diseases
by: Chao Yu, et al.
Published: (2019-12-01) -
The Role and Mechanism of Histone Deacetylases in Acute Kidney Injury
by: Xun Zhou, et al.
Published: (2021-06-01) -
Treatment of Chronic Kidney Diseases with Histone Deacetylase Inhibitors
by: Shougang eZhuang, et al.
Published: (2015-04-01) -
The Role of the Histone Methyltransferase EZH2 in Liver Inflammation and Fibrosis in STAM NASH Mice
by: Seul Lee, et al.
Published: (2020-05-01) -
Histone Deacetylase Inhibitors and Diabetic Kidney Disease
by: Mitchell J. Hadden, et al.
Published: (2018-09-01)